{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:24:45Z","timestamp":1791915885914,"version":"4.3.4"},"reference-count":95,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.det.2024.12.007","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T12:51:22Z","timestamp":1737463882000},"page":"221-229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Hidradenitis Suppurativa Management with Antibiotics and Systemic Therapies"],"prefix":"10.1016","volume":"43","author":[{"given":"Stephen","family":"Kirchner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"Yesil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarannum","family":"Jaleel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.det.2024.12.007_bib1","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jaad.2019.02.067","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: diagnosis, evaluation, and the use of complementary and procedural management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.12.007_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2011.08.047","article-title":"Pathogenesis and pharmacotherapy of Hidradenitis suppurativa","volume":"672","author":"Nazary","year":"2011","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"10.1016\/j.det.2024.12.007_bib3","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-4362.1983.tb02150.x","article-title":"Topical treatment of hidradenitis suppurativa with clindamycin","volume":"22","author":"Clemmensen","year":"1983","journal-title":"Int J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.12.007_bib4","article-title":"Systemic antibiotic therapy in hidradenitis suppurativa: a review on treatment landscape and current issues","volume":"12","author":"Molinelli","year":"2023","journal-title":"Antibiotics (Basel)"},{"issue":"2","key":"10.1016\/j.det.2024.12.007_bib5","article-title":"Topical antibiotic treatment in Dermatology","volume":"12","author":"Dallo","year":"2023","journal-title":"Antibiotics (Basel)"},{"issue":"5 Suppl 1","key":"10.1016\/j.det.2024.12.007_bib6","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.jaad.2015.07.048","article-title":"Local wound care and topical management of hidradenitis suppurativa","volume":"73","author":"Alavi","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2024.12.007_bib7","first-page":"173","article-title":"Management of hidradenitis suppurativa: a U.K. survey of current practice","author":"Ingram","year":"2015","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.12.007_bib8","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15439","article-title":"Efficacy and safety of topical resorcinol 15% versus topical clindamycin 1% in the management of mild-to-moderate hidradenitis suppurativa: a retrospective study","volume":"35","author":"Molinelli","year":"2022","journal-title":"Dermatol Ther"},{"issue":"4","key":"10.1016\/j.det.2024.12.007_bib9","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1159\/000530758","article-title":"Clindamycin-benzoyl peroxide gel compared with clindamycin lotion for hidradenitis suppurativa: a randomized controlled assessor-blinded intra-patient pilot study","volume":"239","author":"Aarts","year":"2023","journal-title":"Dermatology"},{"issue":"5","key":"10.1016\/j.det.2024.12.007_bib10","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1080\/09546634.2016.1273470","article-title":"Effective modified conservative tissue preserving protocol to treat stage I axillary hidradenitis suppurativa: a prospective cohort study of 627 patients with five years follow-up","volume":"28","author":"Shirah","year":"2017","journal-title":"J\u00a0Dermatol Treat"},{"issue":"2","key":"10.1016\/j.det.2024.12.007_bib11","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/00042728-200802000-00012","article-title":"Surgical treatment of hidradenitis suppurativa with gentamicin sulfate: a prospective randomized study","volume":"34","author":"Buimer","year":"2008","journal-title":"Dermatol Surg"},{"issue":"6","key":"10.1016\/j.det.2024.12.007_bib12","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0190-9622(98)70272-5","article-title":"Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa","volume":"39","author":"Jemec","year":"1998","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.12.007_bib13","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jaad.2016.08.001","article-title":"Patterns of antimicrobial resistance in lesions of hidradenitis suppurativa","volume":"76","author":"Fischer","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.12.007_bib14","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2340\/00015555-1841","article-title":"Bacteriology of hidradenitis suppurativa - which antibiotics are the treatment of choice?","volume":"94","author":"Matusiak","year":"2014","journal-title":"Acta Derm Venereol"},{"issue":"7","key":"10.1016\/j.det.2024.12.007_bib15","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/ijd.15459","article-title":"Treatment of hidradenitis suppurativa with tetracycline, doxycycline, or lymecycline: a prospective study","volume":"60","author":"J\u00f8rgensen","year":"2021","journal-title":"Int J Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.12.007_bib16","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13003","article-title":"Hidradenitis suppurativa: clinical characteristics and determinants of treatment efficacy","volume":"32","author":"Vural","year":"2019","journal-title":"Dermatol Ther"},{"issue":"5","key":"10.1016\/j.det.2024.12.007_bib17","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.det.2024.12.007_bib18","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/bjd\/ljad388","article-title":"Treatment of hidradenitis suppurativa evaluation study (THESEUS): a prospective cohort study","volume":"190","author":"Ingram","year":"2023","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.det.2024.12.007_bib19","first-page":"669","article-title":"Potential harms of long-term acne treatment with oral antibiotics","volume":"66","author":"Dao","year":"2020","journal-title":"Can Fam Physician"},{"issue":"4","key":"10.1016\/j.det.2024.12.007_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5070\/D35VW402NF","article-title":"Hidradenitis suppurativa: a practical review of possible medical treatments based on over 350 hidradenitis patients","volume":"19","author":"Scheinfeld","year":"2013","journal-title":"Dermatol Online J"},{"issue":"5437","key":"10.1016\/j.det.2024.12.007_bib21","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1136\/bmj.1.5437.743-a","article-title":"Tetracyclines in pregnancy","volume":"1","author":"Sukhorukikh","year":"1965","journal-title":"Br Med J"},{"issue":"17","key":"10.1016\/j.det.2024.12.007_bib22","first-page":"849","article-title":"Effects of tetracyclines on skeletal growth and dentition. A report by the Nutrition Committee of the Canadian Paediatric Society","volume":"99","author":"Demers","year":"1968","journal-title":"Can Med Assoc J"},{"issue":"1","key":"10.1016\/j.det.2024.12.007_bib23","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/ced.14388","article-title":"Lymecycline vs. clindamycin plus rifampicin in hidradenitis suppurativa treatment: clinical and ultrasonography evaluation","volume":"46","author":"Caposiena Caro","year":"2021","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.12.007_bib24","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1365-2133.2006.07155.x","article-title":"Clindamycin and rifampicin combination therapy for hidradenitis suppurativa","volume":"154","author":"Mendon\u00e7a","year":"2006","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.det.2024.12.007_bib25","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/ced.12933","article-title":"Oral clindamycin and rifampicin combination therapy for hidradenitis suppurativa: a prospective study and 1-year follow-up","volume":"41","author":"Dessinioti","year":"2016","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.12.007_bib26","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000228337","article-title":"The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa","volume":"219","author":"van der Zee","year":"2009","journal-title":"Dermatology"},{"issue":"2","key":"10.1016\/j.det.2024.12.007_bib27","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000228334","article-title":"Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients","volume":"219","author":"Gener","year":"2009","journal-title":"Dermatology"},{"issue":"4","key":"10.1016\/j.det.2024.12.007_bib28","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/bjd.17265","article-title":"Long-term clinical safety of clindamycin and rifampicin combination for the treatment of hidradenitis suppurativa. A Critically Appraised Topic","volume":"180","author":"Albrecht","year":"2019","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.12.007_bib29","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/bjd.17615","article-title":"Prolonged clindamycin and rifampicin for hidradenitis suppurativa: resist to prevent resistance","volume":"180","author":"Hambly","year":"2019","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.12.007_bib30","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/jdv.19725","article-title":"Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa","volume":"38","author":"Aarts","year":"2024","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.det.2024.12.007_bib31","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.jaad.2018.11.035","article-title":"Clindamycin versus clindamycin plus rifampicin in hidradenitis suppurativa treatment: clinical and ultrasound observations","volume":"80","author":"Caposiena Caro","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.det.2024.12.007_bib32","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1124\/dmd.31.7.878","article-title":"In\u00a0vitro metabolism of clindamycin in human liver and intestinal microsomes","volume":"31","author":"Wynalda","year":"2003","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.det.2024.12.007_bib33","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s15010-015-0773-y","article-title":"Pharmacokinetic variability of clindamycin and influence of rifampicin on clindamycin concentration in patients with bone and joint infections","volume":"43","author":"Curis","year":"2015","journal-title":"Infection"},{"issue":"1","key":"10.1016\/j.det.2024.12.007_bib34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000321716","article-title":"Efficacy of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa","volume":"222","author":"Join-Lambert","year":"2010","journal-title":"Dermatology"},{"issue":"1","key":"10.1016\/j.det.2024.12.007_bib35","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jaad.2020.01.007","article-title":"Rifampin-moxifloxacin-metronidazole combination therapy for severe Hurley stage 1 hidradenitis suppurativa: prospective short-term trial and 1-year follow-up in 28 consecutive patients","volume":"88","author":"Delage","year":"2023","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.12.007_bib36","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1111\/jdv.17069","article-title":"Metronidazole for Hidradenitis Suppurativa: future potential treatment applications","volume":"35","author":"Ring","year":"2021","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.det.2024.12.007_bib37","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/jac\/dkv361","article-title":"Efficacy of ertapenem in severe hidradenitis suppurativa: a pilot study in a cohort of 30 consecutive patients","volume":"71","author":"Join-Lambert","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.det.2024.12.007_bib38","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/ijd.14036","article-title":"Ertapenem - a potent treatment for clinical and quality of life improvement in patients with hidradenitis suppurativa","volume":"57","author":"Braunberger","year":"2018","journal-title":"Int J Dermatol"},{"issue":"suppl_1","key":"10.1016\/j.det.2024.12.007_bib39","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1093\/ofid\/ofx163.115","article-title":"More than just an anti-infective agent: a prospective pilot clinical trial to determine the effectiveness of IV ertapenem in severe hidradenitis suppurativa","volume":"4","author":"Ramesh","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.det.2024.12.007_bib40","article-title":"Intramuscular ertapenem for the treatment of severe cases hidradenitis suppurativa","volume":"34","author":"Segura Palacios","year":"2023","journal-title":"J\u00a0Dermatol Treat"},{"issue":"4","key":"10.1016\/j.det.2024.12.007_bib41","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/09546630600830588","article-title":"Hidradenitis suppurativa treated with dapsone: a case series of five patients","volume":"17","author":"Kaur","year":"2006","journal-title":"J\u00a0Dermatol Treat"},{"issue":"4","key":"10.1016\/j.det.2024.12.007_bib42","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1159\/000329023","article-title":"Dapsone therapy for hidradenitis suppurativa: a series of 24 patients","volume":"222","author":"Yazdanyar","year":"2011","journal-title":"Dermatology"},{"issue":"11","key":"10.1016\/j.det.2024.12.007_bib43","first-page":"e12","article-title":"Dapsone to treat moderate-to-severe hidradenitis suppurativa: a retrospective case-series","volume":"22","author":"Baroudi","year":"2023","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.12.007_bib44","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15161","article-title":"Dapsone in hidradenitis suppurativa: a case series of 56 patients","volume":"34","author":"L\u00f3pez-Llunell","year":"2021","journal-title":"Dermatol Ther"},{"issue":"2","key":"10.1016\/j.det.2024.12.007_bib45","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s13555-021-00674-x","article-title":"Dapsone in hidradenitis suppurativa: a systematic review","volume":"12","author":"Rabindranathnambi","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.det.2024.12.007_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdcr.2023.04.025","article-title":"Trimethoprim\/sulfamethoxazole and cephalexin combination therapy in hidradenitis suppurativa patients: a series of 16 cases","volume":"37","author":"Masson","year":"2023","journal-title":"JAAD Case Reports"},{"issue":"2","key":"10.1016\/j.det.2024.12.007_bib47","doi-asserted-by":"crossref","DOI":"10.5070\/D3212025709","article-title":"Extensive hidradenitis suppurativa (HS) Hurly stage III disease treated with intravenous (IV) linezolid and meropenem with rapid remission","volume":"21","author":"Scheinfeld","year":"2015","journal-title":"Dermatol Online J"},{"issue":"Suppl 6","key":"10.1016\/j.det.2024.12.007_bib48","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/jdv.15827","article-title":"Hidradenitis suppurativa in a prepubertal case series: a call for specific guidelines","volume":"33","author":"Offidani","year":"2019","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"11","key":"10.1016\/j.det.2024.12.007_bib49","article-title":"The effect of dalbavancin in moderate to severe hidradenitis suppurativa","volume":"11","author":"Molinelli","year":"2022","journal-title":"Antibiotics (Basel)"},{"issue":"4","key":"10.1016\/j.det.2024.12.007_bib50","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02062-19","article-title":"New evidence and insights on dalbavancin and wound healing in a mouse model of skin infection","volume":"64","author":"Simonetti","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.det.2024.12.007_bib51","first-page":"239","article-title":"The role of androgens and estrogens in hidradenitis suppurativa\u2013a systematic review","volume":"24","author":"Theut Riis","year":"2016","journal-title":"Acta Dermatovenerol Croat"},{"issue":"5, Part B","key":"10.1016\/j.det.2024.12.007_bib52","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ijwd.2021.10.012","article-title":"Clinical considerations in the management of hidradenitis suppurativa in women","volume":"7","author":"Kozera","year":"2021","journal-title":"Int J Women's Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.12.007_bib53","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2310\/7750.2007.00019","article-title":"Hidradenitis suppurativa in 64 female patients: retrospective study comparing oral antibiotics and antiandrogen therapy","volume":"11","author":"Kraft","year":"2007","journal-title":"J\u00a0Cutan Med Surg"},{"issue":"3","key":"10.1016\/j.det.2024.12.007_bib54","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1365-2133.1986.tb05740.x","article-title":"A\u00a0double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa","volume":"115","author":"MORTIMER","year":"1986","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.12.007_bib55","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1093\/ced\/llad385","article-title":"Hidradenitis suppurativa disease control associated with type of hormonal contraceptive use","volume":"49","author":"Huang","year":"2023","journal-title":"Clin Exp Dermatol"},{"issue":"23","key":"10.1016\/j.det.2024.12.007_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232315250","article-title":"The role of hormones in hidradenitis suppurativa: a systematic review","volume":"23","author":"Abu Rached","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.det.2024.12.007_bib57","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/ajd.12362","article-title":"A\u00a0case series of 20 women with hidradenitis suppurativa treated with spironolactone","volume":"56","author":"Lee","year":"2015","journal-title":"Australas J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.12.007_bib58","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jaad.2018.06.063","article-title":"Antiandrogen therapy with spironolactone for the treatment of hidradenitis suppurativa","volume":"80","author":"Golbari","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.12.007_bib59","doi-asserted-by":"crossref","DOI":"10.1097\/JW9.0000000000000135","article-title":"Spironolactone in hidradenitis suppurativa: a single-center","volume":"10","author":"Masson","year":"2024","journal-title":"International Journal of Women's Dermatology"},{"issue":"4","key":"10.1016\/j.det.2024.12.007_bib60","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/ced.14119","article-title":"Spironolactone therapy for hidradenitis suppurativa","volume":"45","author":"Quinlan","year":"2020","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.12.007_bib61","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jaad.2021.12.005","article-title":"Trends in the prescribing pattern of spironolactone for acne and hidradenitis suppurativa in adolescents","volume":"87","author":"Horissian","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.12.007_bib62","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.det.2021.12.004","article-title":"Hormonal treatment of acne and hidradenitis suppurativa in adolescent patients","volume":"40","author":"Svoboda","year":"2022","journal-title":"Dermatol Clin"},{"issue":"6","key":"10.1016\/j.det.2024.12.007_bib63","first-page":"44","article-title":"Finasteride in hidradenitis suppurativa: a \"male\" therapy for a predominantly \"female\" disease","volume":"9","author":"Khandalavala","year":"2016","journal-title":"J\u00a0Clin Aesthet Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.12.007_bib64","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/ced.14847","article-title":"Antiandrogen therapy in hidradenitis suppurativa: finasteride for females","volume":"47","author":"Babbush","year":"2022","journal-title":"Clin Exp Dermatol"},{"issue":"11","key":"10.1016\/j.det.2024.12.007_bib65","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15837","article-title":"Topical finasteride: a potential therapeutic option for hidradenitis suppurativa","volume":"35","author":"Manfredini","year":"2022","journal-title":"Dermatol Ther"},{"issue":"8","key":"10.1016\/j.det.2024.12.007_bib66","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.3390\/ijms24086969","article-title":"Metformin treatment of hidradenitis suppurativa: effect on metabolic parameters, inflammation, cardiovascular risk biomarkers, and immune mediators","volume":"24","author":"Hambly","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"23","key":"10.1016\/j.det.2024.12.007_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21238960","article-title":"A\u00a0molecular perspective on the potential benefits of metformin for the treatment of inflammatory skin disorders","volume":"21","author":"Chang","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.det.2024.12.007_bib68","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/j.1468-3083.2012.04668.x","article-title":"Metformin for the treatment of hidradenitis suppurativa: a little help along the way","volume":"27","author":"Verdolini","year":"2013","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.det.2024.12.007_bib69","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/09546634.2019.1592100","article-title":"Metformin use in hidradenitis suppurativa","volume":"31","author":"Jennings","year":"2020","journal-title":"J\u00a0Dermatol Treat"},{"issue":"4","key":"10.1016\/j.det.2024.12.007_bib70","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40257-019-00442-w","article-title":"Is there a role for antiandrogen therapy for hidradenitis suppurativa? A systematic review of published data","volume":"20","author":"Nikolakis","year":"2019","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.12.007_bib71","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jaad.2008.11.911","article-title":"Hidradenitis suppurativa: a comprehensive review","volume":"60","author":"Alikhan","year":"2009","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.12.007_bib72","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0190-9622(84)70199-X","article-title":"Evaluation of isotretinoin treatment of hidradenitis suppurativa","volume":"11","author":"Dicken","year":"1984","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.12.007_bib73","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2230.1986.tb00512.x","article-title":"Failure of treatment of familial widespread hidradenitis suppurativa with isotretinoin","volume":"11","author":"NORRIS","year":"1986","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.12.007_bib74","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0190-9622(99)70530-X","article-title":"Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa","volume":"40","author":"Boer","year":"1999","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.12.007_bib75","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000182261","article-title":"Absence of efficacy of oral isotretinoin in hidradenitis suppurativa: a retrospective study based on patients\u2019 outcome assessment","volume":"218","author":"Soria","year":"2008","journal-title":"Dermatology"},{"issue":"4","key":"10.1016\/j.det.2024.12.007_bib76","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/09546634.2019.1670779","article-title":"Isotretinoin in the treatment of hidradenitis suppurativa: a retrospective study","volume":"32","author":"Patel","year":"2021","journal-title":"J\u00a0Dermatol Treat"},{"issue":"7","key":"10.1016\/j.det.2024.12.007_bib77","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/ced.13944","article-title":"Could isotretinoin flare hidradenitis suppurativa? A case series","volume":"44","author":"Gallagher","year":"2019","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.12.007_bib78","first-page":"670","article-title":"Efficacy and toxicity of classical immunosuppressants, retinoids and biologics in hidradenitis suppurativa","volume":"11","author":"Das","year":"2022","journal-title":"J\u00a0Clin Med"},{"issue":"1","key":"10.1016\/j.det.2024.12.007_bib79","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1365-2133.2010.10071.x","article-title":"Long-term results of acitretin therapy for hidradenitis suppurativa. Is acne inversa also a misnomer?","volume":"164","author":"Boer","year":"2011","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.12.007_bib80","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/bjd.12884","article-title":"Acitretin treatment for hidradenitis suppurativa: a prospective series of 17 patients","volume":"171","author":"Matusiak","year":"2014","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.12.007_bib81","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/1203475416659858","article-title":"Acitretin:Monotherapy or combined therapy for hidradenitis suppurativa?","volume":"21","author":"Tan","year":"2017","journal-title":"J\u00a0Cutan Med Surg"},{"issue":"6","key":"10.1016\/j.det.2024.12.007_bib82","doi-asserted-by":"crossref","first-page":"650","DOI":"10.4103\/0019-5154.91821","article-title":"A\u00a0study on the management of hidradenitis suppurativa with retinoids and surgical excision","volume":"56","author":"Puri","year":"2011","journal-title":"Indian J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.12.007_bib83","first-page":"155","article-title":"Alitretinoin: a useful agent in the treatment of hidradenitis suppurativa, especially in women of child-bearing age","volume":"150","author":"Verdolini","year":"2015","journal-title":"G\u00a0Ital Dermatol venereol Organo Uff Soc Ital Dermatol Sifilogr"},{"issue":"2","key":"10.1016\/j.det.2024.12.007_bib84","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000332846","article-title":"The anti-inflammatory drug colchicine lacks efficacy in hidradenitis suppurativa","volume":"223","author":"van der Zee","year":"2011","journal-title":"Dermatology"},{"issue":"2","key":"10.1016\/j.det.2024.12.007_bib85","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1172\/JCI118147","article-title":"Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils","volume":"96","author":"Cronstein","year":"1995","journal-title":"J\u00a0Clin Invest"},{"issue":"3","key":"10.1016\/j.det.2024.12.007_bib86","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/ijd.13428","article-title":"Hidradenitis suppurativa treated with tetracycline in combination with colchicine: a prospective series of 20 patients","volume":"56","author":"Armyra","year":"2017","journal-title":"Int J Dermatol"},{"issue":"2\u20133","key":"10.1016\/j.det.2024.12.007_bib87","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0162-3109(00)00192-2","article-title":"Mechanisms of action of cyclosporine","volume":"47","author":"Matsuda","year":"2000","journal-title":"Immunopharmacology"},{"issue":"5","key":"10.1016\/j.det.2024.12.007_bib88","first-page":"289p","article-title":"Cyclosporin-responsive hidradenitis suppurativa","volume":"88","author":"Buckley","year":"1995","journal-title":"J\u00a0R Soc Med"},{"issue":"6","key":"10.1016\/j.det.2024.12.007_bib89","doi-asserted-by":"crossref","first-page":"e278","DOI":"10.1016\/j.jaad.2012.06.011","article-title":"Recalcitrant severe hidradenitis suppurativa successfully treated with cyclosporine A","volume":"67","author":"Bianchi","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.12.007_bib90","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3109\/09546634.2015.1088128","article-title":"Cyclosporine treatment of severe Hidradenitis suppurativa \u2013 a case series","volume":"27","author":"Anderson","year":"2016","journal-title":"J\u00a0Dermatol Treat"},{"issue":"5 Suppl 1","key":"10.1016\/j.det.2024.12.007_bib91","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.jaad.2015.07.049","article-title":"Scientific evidence for the use of current traditional systemic therapies in patients with hidradenitis suppurativa","volume":"73","author":"Alhusayen","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.12.007_bib92","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1365-2230.2005.01983.x","article-title":"Treatment of recalcitrant hidradenitis suppurativa with oral ciclosporin","volume":"31","author":"Rose","year":"2006","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.12.007_bib93","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaad.2016.06.001","article-title":"Low-dose systemic corticosteroid treatment for recalcitrant hidradenitis suppurativa","volume":"75","author":"Wong","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.12.007_bib94","article-title":"Methotrexate is of limited value in the treatment of hidradenitis suppurativa","volume":"27","author":"Jemec","year":"2002","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.12.007_bib95","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/bjd.14086","article-title":"Azathioprine lacks efficacy in hidradenitis suppurativa: a retrospective study of nine patients","volume":"174","author":"Nazary","year":"2016","journal-title":"Br J Dermatol"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524001074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524001074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T17:31:22Z","timestamp":1751391082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863524001074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":95,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0733863524001074"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2024.12.007","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hidradenitis Suppurativa Management with Antibiotics and Systemic Therapies","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2024.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}